Targeting growth factor receptors with fusion toxins.
暂无分享,去创建一个
[1] F. Studier,et al. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. , 1986, Journal of molecular biology.
[2] D. Mckay,et al. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Ozanne,et al. Human squamous cell lung cancers express increased epidermal growth factor receptors. , 1984, The Journal of clinical investigation.
[4] R. Reynolds,et al. Characterization of epidermal growth factor receptor in normal and neoplastic human endometrium , 1990, Cancer.
[5] I. Pastan,et al. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. , 1988, The Journal of biological chemistry.
[6] I. Pastan,et al. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[7] L. Ghosh,et al. Epidermal growth factor in the normal and neoplastic kidney and bladder. , 1988, The Journal of urology.
[8] T. Waldmann,et al. IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. , 1990, The Journal of biological chemistry.
[9] T. Waldmann,et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin , 1989, Nature.
[10] T. Hirano,et al. TETSUYA TAGA , YOSHIKAZU KAWANISHI , 2003 .
[11] M. Gregoriou,et al. Epidermal growth factor receptor expression in 72 meningiomas , 1990, Cancer.
[12] J. Case,et al. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[13] I. Pastan,et al. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. , 1990, Cancer research.
[14] T. Waldmann,et al. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[15] I. Pastan,et al. Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] I. Pastan,et al. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. , 1991, The Journal of biological chemistry.
[17] G. Paludetti,et al. Receptors for epidermal growth factor and steroid hormones in primary laryngeal tumors , 1991, Cancer.
[18] I. Pastan,et al. Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. , 1990, The Journal of biological chemistry.
[19] I. Pastan,et al. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[20] H. Asaoku,et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.
[21] I. Pastan,et al. Cytotoxic activity of a recombinant fusion protein between interleukin 4 and Pseudomonas exotoxin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Gelmann,et al. Role of transforming growth factor ‐α in human prostate cancer cell growth , 1989 .
[23] I. Pastan,et al. IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. , 1988, Journal of immunology.
[24] D. Heimbrook,et al. Epidermal growth factor receptor binding is affected by structural determinants in the toxin domain of transforming growth factor-alpha-Pseudomonas exotoxin fusion proteins , 1989, Molecular and cellular biology.
[25] I. Pastan,et al. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). , 1991, Cancer research.
[26] I. Pastan,et al. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. , 1990, The Journal of biological chemistry.
[27] M. Melamed,et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. , 1986, Cancer research.
[28] I. Pastan,et al. Pseudomonas exotoxin: chimeric toxins. , 1989, The Journal of biological chemistry.
[29] I. Pastan,et al. Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity. , 1990, The Journal of biological chemistry.
[30] I. Pastan,et al. Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli , 1987, Cell.
[31] I. Pastan,et al. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[32] I. Pastan,et al. Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. , 1991, Cancer Research.
[33] I. Pastan,et al. Cardiac allograft survival in mice treated with IL-2-PE40. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[34] I. Pastan,et al. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. , 1991, Cancer research.
[35] W. Greene,et al. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen , 1984, The Journal of experimental medicine.
[36] J. Bauer,et al. Regulation of interleukin‐6 receptor expression in human monocytes and hepatocytes , 1989, FEBS letters.
[37] I. Pastan,et al. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[38] I. Pastan,et al. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. , 1989, The Journal of biological chemistry.
[39] I. Pastan,et al. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[40] T. Waldmann,et al. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. , 1988, The Journal of biological chemistry.
[41] J. Case,et al. Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. , 1991, International journal of immunopharmacology.
[42] I. Pastan,et al. Cell-Specific Toxicity of a Chimeric Protein Composed of Interleukin-6 and Pseudomonas Exotoxin (IL6-PE40) on Tumor Cells , 1990, Molecular and cellular biology.
[43] I. Pastan,et al. Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. , 1990, The Journal of biological chemistry.
[44] I. Pastan,et al. Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] T. Waldmann,et al. Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. , 1984, The Journal of clinical investigation.